Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2749-2753

  Juweid, Malik E ^a   Zhang, Cun Hui ^a   Blumenthal, Rosalyn D ^a   Sharkey, Robert M ^a   Dunn, Robert ^a   Dunlop, Douglas ^a   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Carcinoembryonic antigen; Hematologic toxicity; Monoclonal antibodies; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 131; IMMU 14; IMMU 4; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY MN 14 I 131; MONOCLONAL ANTIBODY NP 4 I 131; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; BLOOD TOXICITY; BREAST CARCINOMA; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; FEMALE; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVARY CARCINOMA; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THYROID MEDULLARY CARCINOMA;

EID: 0031459397     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2749::aid-cncr55>3.0.co;2-8     Document Type: Conference Paper

References (28)

1. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994;12:1561-71.
2. Larson SM, Leibel SA, Cheung NKV. Radioisotope conjugates. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:496-511.
3. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993;94:297-312.
4. DeNardo GL, DeNardo SJ, Macey DJ, Shen S, Kroger LA. Overview of radiation myelotoxicity secondary to radioimmunotherapy using I-131-Lym-1 as a model. Cancer 1994;73:1038-48.
5. Juweid M, Sharkey RM, Behr T, Swayne LC, Dunn R, Goldenberg DM. Radioimmunotherapy in patients with CEA-producing cancers and small-volume disease using I-131-labeled anti-CEA monoclonal antibody NP-4 F(ab′)2. J Nucl Med 1996;37:1504-10.
6. 131I-labeled anti-CEA antibodies. J Nucl Med 1996;37:905-11.
7. 131I-labeled anti-CEA murine monoclonal antibody IgG. J Nucl Med 1997;38:858-70.
8. 131I-CC49 in colorectal cancer. Cancer 1994;73:1057-66.
9. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, et al. Treatment of metastatic prostate cancer with radiolabeled antibody CC49. J Nucl Med 1994;35:1017-22.
10. Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 1995;36:586-92.
11. Breitz HB, Fisher DR, Wessels B. Correlation of bone marrow absorbed dose estimates with marrow toxicity [abstract]. Tumor Targeting 1996;2:171-2.
12. Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983;43:686-92.
13. Sharkey RM, Goldenberg DM, Goldenberg H, Lee RE, Balance C, Pawlyk D, et al. Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic and targeting properties in humans. Cancer Res 1990;50:2823-31.
14. Hansen HJ, Goldenberg DM, Newman E, Grebenau R, Sharkey RM. Characterization of second generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993;71:3478-85.
15. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, et al. Clinical evaluation of tumor targeting with a high affinity anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993;71:2081-96.
16. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1990;31:508-11.
17. Bigler R, Zanzonico PB, Leonard R, Cosma M, Primus FJ, Alger E, et al. Bone marrow dosimetry for monoclonal antibody therapy. Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN. 1986:535-44.
18. Siegel JA, Wessels BW, Watson EE, Stabin MG, Vriesendorp HM, Bradley EW, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharmacol 1990;3:213-33.
19. Fisher DR. Radiation dosimetry for radioimmunotherapy. Cancer 1994;73:905-11.
20. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-94.
21. Loevinger R, Berman M. A revised scheme for calculating the absorbed dose from biologically distributed radionuclide. MIRD pamphlet no. 1, revised. New York: Society for Nuclear Medicine, 1976.
22. Cloutier RV, Watson EE, Rohrer RH. Calculating the radiation dose to an organ. J Nucl Med 1973;14:53-5.
23. Johnson RA, Wichern DW. Applied multivariate statistical analysis. Englewood Cliffs, NJ: Prentice Hall, 1988.
24. Chabner BA. Anticancer drugs. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: principles & practices of oncology, Philadelphia: JB Lippincott, 1993:325-417.
25. Blumenthal RD, Alisauskas R, Juweid M, Sharkey RM, Goldenberg DM. Defining the optimal spacing between repeat radioantibody doses in experimental models: is there an accurate toxicity endpoint? [abstract]. Tumor Targeting 1996;2:151-2.
26. Reske SN, Karstens JH, Gloeckner MW, Schwarz A, Steinstraesser A, Ammon J, et al. Radioimmunoimaging of bone marrow: results in patients with breast cancer and skeletal metastases and patients with malignant melanoma. Lancet 1989;2:299-301.
27. Duncker CM, Carrio I, Berna L, Estorch M, Alonso C, Ojeda B, et al. Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer. J Nucl Med 1990;31:1450-5.
28. 99mTc-MDP bone scan. Korean J Nucl Med 1994;28:89-97.